Buchumschlag

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Thanawin Pramotedham, Yong Chuan Tan
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
von: Mary Yue Wang, et al.
Veröffentlicht: (2026)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
von: Lucie Simonis, et al.
Veröffentlicht: (2025)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
von: Eduardo Vilar‐Gomez, et al.
Veröffentlicht: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
von: Stephanie Tsai, et al.
Veröffentlicht: (2025)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
von: Shuai Xia, et al.
Veröffentlicht: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
von: Bingqiong Wang, et al.
Veröffentlicht: (2025)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
von: Lucie Simonis, et al.
Veröffentlicht: (2025)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
von: Supachaya Sriphoosanaphan, et al.
Veröffentlicht: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
von: Luis Calzadilla Bertot, et al.
Veröffentlicht: (2025)

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation
von: David Tornai, et al.
Veröffentlicht: (2025)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
von: David Tornai, et al.
Veröffentlicht: (2026)

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
von: Nina Kimer, et al.
Veröffentlicht: (2024)

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
von: Adriana Palom, et al.
Veröffentlicht: (2026)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
von: Mo‐Yao Tan, et al.
Veröffentlicht: (2024)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
von: Emily Stephenson, et al.
Veröffentlicht: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
von: Jimmy Che‐To Lai, et al.
Veröffentlicht: (2026)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
von: Mary Yue Wang, et al.
Veröffentlicht: (2025)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
von: Abdulrahman Ismaiel
Veröffentlicht: (2026)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
von: Huiying Lin, et al.
Veröffentlicht: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
von: Louise J. M. Alferink, et al.
Veröffentlicht: (2024)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
von: Glenn Jun Kit Ho, et al.
Veröffentlicht: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
von: Bernardo de Faria Moraes, et al.
Veröffentlicht: (2026)

Editorial: Decoding Gut Failure in Cirrhosis—Villin‐1 and the Emergence of a Seventh Organ Failure. Authors' Reply
von: David Tornai, et al.
Veröffentlicht: (2026)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
von: Ting Wang, et al.
Veröffentlicht: (2024)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
von: William Chai, et al.
Veröffentlicht: (2025)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
von: Deliang Huang, et al.
Veröffentlicht: (2026)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
von: Zhanbo Qu
Veröffentlicht: (2026)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
von: Yu Shi, et al.
Veröffentlicht: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
von: Sai Kiran Kuchana, et al.
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
von: Mei Chin Lim, et al.
Veröffentlicht: (2026)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
von: Yee Hui Yeo, et al.
Veröffentlicht: (2026)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
von: Andrew W. Nguyen, et al.
Veröffentlicht: (2026)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Soroor Owrangi, et al.
Veröffentlicht: (2024)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
von: Christian Labenz, et al.
Veröffentlicht: (2026)

Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions
von: Julian Pohl, et al.
Veröffentlicht: (2025)

Editorial: Quantity is important!
von: Chee‐Kiat Tan
Veröffentlicht: (2024)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
von: Bernardo de Faria Moraes, et al.
Veröffentlicht: (2026)

Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort
von: Scott Silvey, et al.
Veröffentlicht: (2025)